Remove Funds Remove Negotiation Remove Sale
article thumbnail

Striking the Balance: Key Negotiation Points in Today’s Agreements

Focus Investment Banking

Striking the Balance: Key Negotiation Points in Today’s Agreements The M&A landscape is always transforming. Letters of Intent (LOIs) have evolved from brief outlines of deal terms to detailed blueprints, setting the stage for negotiations long before the purchase agreement is drafted.

article thumbnail

MergersCorp Launches Specialized Advisory Service for FINMA-Regulated Divestitures in Switzerland

MergersCorp M&A International

For businesses operating under FINMA’s stringent oversight, a successful sale demands highly specialized advisory expertise. M&A Sale of FINMA Securities House Activities: Facilitating complex sales of securities firms, addressing diverse and high-risk regulated activities, from securities trading to market-making and underwriting.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Navigating Buyer Options, Key Deal Terms, and the Process

Focus Investment Banking

Business owners often dont know where to start with these steps when considering a sale or investment deal. What are the key terms I should negotiate in a sale or investment deal? Negotiation goes beyond just the price. Key terms include: Deal Structure : Cash at close, seller notes, stock or asset sale.

Sale 52
article thumbnail

Key Financial Metrics Buyers Look for Before Acquiring a Business

Lake Country Advisors

In this guide, we’ll explain the key metrics buyers care about, why each matters, and how you can get your numbers in shape before a sale. Why Financial Metrics Matter in a Business Sale Most deals fall apart not because the business lacks potential, but because the numbers don’t hold up under scrutiny.

article thumbnail

JPMorgan's top biotech and pharma picks for the second half

CNBC: Investing

"The sector [should be] able to largely mitigate the impact of tariffs in the mid/long term through manufacturing repatriation and 2) [there's] no clear path for MFN ["most favored nation"] to move forward without Congressional approval (outside of IRA price negotiations)," Schott said.

S&P 52
article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales. The sale of Poseida Therapeutics, a cell and gene therapy-focused company, for up to $1.5 billion sale of Carmot Therapeutics, a promising Swiss GLP-1 drug developer, further underscores the sectors vitality.

M&A 64
article thumbnail

Uncertainty looms as 2025 nears the halfway mark. How to make sure your portfolio is prepared

CNBC: Investing

Traders' hopes for progress in trade negotiations, along with solid first-quarter earnings, helped the market recover since then, however. Be sure to avoid violating the wash-sale rule, which involves selling an asset at a loss and then buying a "substantially identical" security within 30 days before or after the transaction.

Portfolio 114